View the public protocol
GlaxoSmithKline, Harvard Pilgrim Health Care Institute, CVS Health, Carelon Research, Optum Epidemiology. Postmarketing commitment safety study of HZ/su to evaluate pregnancy exposures and outcomes in immunodeficient or immunosuppressed women between 18 and 49 years of age (EPI-ZOSTER-039 VS US DB 214420) (EUPAS104070; Study ID 105603). Amsterdam: European Medicines Agency (EMA); 2023 Mar 31. Available from: https://catalogues.ema.europa.eu/node/3755/administrative-details
